ASG Events chief executive Erick Oosthuizen says their commitment to supporting a charity will be a key element of the Takealot Tour of Good Hope road race next month.
South Africa’s premier road cycling tour takes place in the Cape Winelands from March 4 to 8 and will have UCI status for the first time.
With plenty of interest in the event from riders both local and abroad, Oosthuizen said they would use the occasion to raise awareness about the Olive Children’s Foundation.
“ASG Sport Solutions has always been as passionate about development and making a significant difference to the community,” said Oosthuizen.
“Known for bringing innovative, sometimes rare, brands to consumers, this makes the partnership with the Olive Children’s Foundation (OCF) a perfect fit as it was established to bring relief to families of children with rare conditions.”
OCF advertising and public relations manager Megan Schumann said they were extremely proud to be involved with the Tour of Good Hope, during which cyclists could support the foundation in several ways.
“On entering, the riders will have the opportunity to make a donation to the foundation and they will also be able to buy the specialised limited edition ASG cycling gear branded with OCF logos.
“At the end of the tour, there will be blood donation stations for supporters and riders to register and even donate blood if they are up to it.
“Apart from blood donations, financial donations and the various other ways to get involved, pure awareness about the OCF is crucial so that more children with rare diseases can be diagnosed and supported.
“Every time someone follows or shares any of our social media platforms, we get one step closer to finding eligible donors and potential DBA patients that have not yet been diagnosed.”
With the slogan of “Save a Life, it’s in your Blood”, the foundation was named after a young girl, Olive, who was just six weeks old when she went into heart failure due to the anaemia caused by a rare genetic disorder – Diamond-Blackfan Anaemia (DBA).
Schumann said DBA resulted in bone marrow failure, early onset cancers and congenital abnormalities, which required patients to receive regular blood transfusions and medical treatment throughout their lives.